NORWOOD, Mass. — September 14, 2026
Corbus Pharmaceuticals Holdings, Inc. announced positive topline results from its CANYON-1 Phase 1b study of CRB-913, an orally administered, peripherally restricted CB1 inverse agonist being developed for obesity. The 16-week randomized, double-blind, placebo-controlled trial demonstrated statistically significant weight loss across all three dose levels, with the 60 mg dose producing a 5.0% least-squares mean reduction in body weight at Week 12 versus 0% for placebo (p<0.0001). No plateau in weight loss was observed at any dose. CRB-913 was generally well tolerated, with psychiatric adverse events broadly comparable with published data for marketed GLP-1 therapies and an emerging gastrointestinal tolerability profile that Corbus believes may differentiate the program. The company plans to advance CRB-913 into Phase 2 development, positioning the candidate as a potential oral, non-incretin approach to obesity treatment.
CRB-913 Delivers Rapid Weight Loss Without Plateau
The CANYON-1 efficacy findings provide early clinical support for CRB-913’s potential as a new class of oral obesity medicine. The study enrolled 254 obese, non-diabetic adults at 15 U.S. sites, with participants randomized equally to placebo or once-daily CRB-913 doses of 20 mg, 40 mg or 60 mg. At Week 12, placebo-adjusted weight loss reached 2.8% at 20 mg, 3.3% at 40 mg and 5.0% at 60 mg, with all comparisons statistically significant. In the 60 mg cohort, 44.4% of participants who completed the study achieved at least 5% weight loss, while 6.7% lost more than 7.5%; the highest recorded reduction was 13.4% from baseline. The absence of an observed plateau through 12 weeks is an important development signal for the company as it prepares longer-duration testing. Corbus is also evaluating whether CRB-913 could eventually be combined with GLP-1 therapy, potentially creating a broader positioning strategy for patients who require additional or alternative mechanisms for weight management.
Safety Profile Supports Further Clinical Development
Safety and tolerability findings from CANYON-1 support continued clinical evaluation of CRB-913, while the company continues to monitor psychiatric and gastrointestinal effects associated with the CB1 mechanism. Psychiatric treatment-emergent adverse events were generally infrequent, mild to moderate and transient, with no serious or severe psychiatric adverse events and no cases of suicidality reported. One participant experienced transient moderate depressive symptoms among the 188 participants receiving CRB-913, while irritability was the most common psychiatric adverse event and remained mild. The company’s cross-trial comparisons indicated psychiatric event rates broadly in line with published data for liraglutide, semaglutide and tirzepatide, although Corbus emphasized that these comparisons were not head-to-head studies. Gastrointestinal events were also generally mild or moderate, with no serious or severe cases reported. Treatment discontinuations due to adverse events ranged from 3.1% to 13.1% across CRB-913 doses, which Corbus said was within the range reported for approved oral GLP-1 medicines and below historical discontinuation rates associated with the more brain-penetrant CB1 inverse agonist monlunabant..
Advertisement
Corbus Prepares CRB-913 for Phase 2 Development
The positive CANYON-1 results establish the next stage of Corbus’ obesity development strategy, with the company planning regulatory discussions and a Phase 2 monotherapy study in the first half of 2027. The full dataset is scheduled for a late-breaking presentation at ObesityWeek 2026 in November, providing an opportunity for broader review of the efficacy, safety and tolerability findings. CRB-913 is designed to selectively target CB1 receptors outside the central nervous system, with the objective of retaining the metabolic effects of CB1 inverse agonism while limiting the psychiatric liabilities associated with earlier centrally acting compounds. Corbus is also assessing combination development with GLP-1 therapy as it explores opportunities to broaden the candidate’s clinical utility. With statistically significant weight loss, continued reductions without an observed plateau and a generally favorable early safety profile, CRB-913 is emerging as the lead asset in Corbus’ strategy to develop oral, non-incretin therapies for obesity.
Source: Corbus Pharmaceuticals press release
